Pregnancy as a Stress Test: What Gestational Diabetes Reveals About Long-Term Health
Cassie Shortsleeve's latest reporting for Two Truths reframes gestational diabetes from a temporary pregnancy complication into something far more consequential: a metabolic warning flare. Drawing on an interview with Dr. Camille Powe, co-director of Massachusetts General Hospital's Diabetes in Pregnancy Program, the piece argues that the medical system routinely fails women by treating gestational diabetes as a problem that ends at delivery. The reality, Shortsleeve contends, is that it marks the beginning of a lifelong health trajectory that most patients are never told about.
The central metaphor is striking. Dr. Powe describes pregnancy itself as a diagnostic instrument:
Pregnancy can be like a stress test. There are a lot of physiological changes that can really give you a window into someone's chronic disease risk.
The numbers back this up. Up to half of women with gestational diabetes eventually develop type 2 diabetes, and their risk is roughly ten times higher than that of women who never had the condition. These are not small elevations in risk. They represent a fundamental shift in metabolic trajectory, yet the article makes clear that most women walk out of their postpartum appointments with little awareness of what lies ahead.
A System That Loses the Thread
Perhaps the most damning section of the piece deals with the fragmentation of care. OB/GYN practices, midwifery clinics, and primary care offices often operate in separate electronic health record systems. A gestational diabetes diagnosis made in one setting may never surface in another. Shortsleeve puts it bluntly: unless a patient personally informs her primary care physician, that doctor may have no idea the diagnosis ever existed.
This is a systemic failure, not an individual one. The American College of Obstetricians and Gynecologists recommends postpartum glucose screening for all women who had gestational diabetes, yet fewer than half actually receive it. The article explains part of the reason: the standard A1C test, which measures average blood sugar over two to three months, produces misleadingly normal results in postpartum women because their red blood cells have shorter lifespans after pregnancy. The recommended alternative, a two-hour oral glucose tolerance test, is more accurate but also more burdensome for a sleep-deprived new parent juggling feeding schedules and recovery.
It is worth pausing on this structural mismatch. The healthcare system knows the right test to use. It knows the right population to screen. It knows the stakes. And yet the logistics of new parenthood, combined with inadequate care coordination, mean that the majority of at-risk women slip through the cracks. The article names this gap but stops short of proposing solutions beyond individual advocacy, which is understandable for a newsletter format but leaves the systemic question hanging.
The Breastfeeding Connection
One of the more scientifically interesting claims in the piece concerns breastfeeding's potential role in reducing future diabetes risk. Dr. Powe offers a biochemical explanation:
Blood sugar is an ingredient in milk. You need glucose and galactose to make lactose, which is the sugar in breast milk, so you're using sugar when you're lactating.
The mechanism is intuitive: lactation draws glucose from the bloodstream to produce milk, which could improve insulin sensitivity over time. Research published in Diabetes Care supports a link between lactation duration and lower long-term type 2 diabetes incidence. However, this finding comes with an important caveat that the article acknowledges in passing: the metabolic benefits of breastfeeding are not fully understood, and the research base on maternal health remains thin.
A counterpoint worth raising is that breastfeeding is not universally accessible or feasible. Factors ranging from latch difficulties to workplace policies to medication incompatibilities mean that framing breastfeeding as a diabetes prevention strategy, while scientifically grounded, risks adding another layer of pressure to an already fraught postpartum period. The article does not dwell on this tension, though it does note Dr. Powe's point that metformin is compatible with breastfeeding, offering a pharmacological alternative for blood sugar management during lactation.
Prevention Works, but Funding Is Under Threat
The piece highlights the landmark Diabetes Prevention Program, a major clinical trial that demonstrated lifestyle changes, including modest weight loss, 150 minutes of weekly exercise, and dietary improvements, can reduce type 2 diabetes risk by 58 percent. Metformin, meanwhile, reduced risk by 31 percent. In women with a history of gestational diabetes specifically, the two approaches were roughly equally effective.
These are remarkable effect sizes, and they underscore the tragedy of the article's political coda. Shortsleeve reports that ongoing follow-up studies and prevention programs inspired by the original trial are now facing significant funding cuts under the current administration. Dr. Powe calls the Diabetes Prevention Program one of the most important studies in chronic disease research:
It's one of the most important studies in chronic disease research.
Cutting funding for diabetes prevention while gestational diabetes rates have climbed 36 percent since 2016 is a policy contradiction that deserves more scrutiny than a single paragraph can provide. The article gestures at this tension without fully exploring it, though it is fair to say that a maternal health newsletter may not be the venue for a deep dive into federal appropriations politics.
Environmental Risk and Health Equity
The article's final point touches on two increasingly important dimensions of gestational diabetes: environmental exposure and racial disparities. A recent Mount Sinai review linked higher PFAS exposure, the so-called "forever chemicals" found in nonstick coatings, food packaging, and water supplies, to increased gestational diabetes risk. This finding adds an environmental justice dimension to a condition already marked by significant racial and ethnic disparities. Black, Hispanic, American Indian, Alaska Native, Native Hawaiian, and Pacific Islander communities face elevated risk, which the article correctly attributes to long-standing inequities in access to care and health resources rather than to biology alone.
These are important threads that the piece weaves together without overstating the connections. The implication is clear: gestational diabetes is not simply a matter of individual metabolism. It sits at the intersection of environmental policy, healthcare infrastructure, racial equity, and chronic disease prevention.
Bottom Line
Shortsleeve's reporting makes a compelling case that gestational diabetes deserves far more clinical attention than it typically receives, both during pregnancy and in the years that follow. The article is at its strongest when it exposes the structural failures, fragmented medical records, inadequate postpartum screening, and threatened research funding, that leave women navigating long-term metabolic risk largely on their own. Where it pulls its punches is in the realm of solutions: the closing advice to "work with your provider to build an individualized plan" places the burden squarely on patients in a system that the article itself has shown to be poorly equipped for continuity of care. The science here is sound, the reporting is thorough, and the gap between what the evidence shows and what the healthcare system actually delivers is, as always, the real story.